{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:04:39Z","timestamp":1781532279850,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.intimp.2019.105967","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T05:02:31Z","timestamp":1572066151000},"page":"105967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers"],"prefix":"10.1016","volume":"77","author":[{"given":"Christian","family":"Bailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.105967_b0005","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/0018578717734877","article-title":"Formulary drug review: edaravone","volume":"52","author":"Ali","year":"2017","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.intimp.2019.105967_b0010","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40262-018-0655-4","article-title":"Two decades-long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics","volume":"57","author":"Dash","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2019.105967_b0015","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7150\/thno.18219","article-title":"Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability","volume":"7","author":"Jin","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2019.105967_b0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3164\/jcbn.17-62","article-title":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?","volume":"62","author":"Watanabe","year":"2018","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.intimp.2019.105967_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.341","article-title":"Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma","volume":"8","author":"Akaiwa","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2019.105967_b0030","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/j.1440-1681.2009.05178.x","article-title":"Development of cardiac dysfunction induced by repetitive transient myocardial ischemia is inhibited by edaravone in conscious rats","volume":"36","author":"Toyota","year":"2009","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.intimp.2019.105967_b0035","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.2147\/DDDT.S144807","article-title":"Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor","volume":"1","author":"Zhang","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/etm.2011.352","article-title":"Beyond free radical scavenging: beneficial effects of edaravone (Radicut) in various diseases (Review)","volume":"3","author":"Kikuchi","year":"2012","journal-title":"Exp. The.r Med."},{"key":"10.1016\/j.intimp.2019.105967_b0045","first-page":"467","article-title":"Edaravone attenuates traumatic brain injury through anti-inflammatory and anti-oxidative modulation","volume":"18","author":"Zhang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.intimp.2019.105967_b0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.14336\/AD.2018.0513","article-title":"The anti-inflammatory and anti-oxidant mechanisms of the Keap1\/Nrf2\/ARE signaling pathway in chronic diseases","volume":"10","author":"Tu","year":"2019","journal-title":"Aging Dis."},{"key":"10.1016\/j.intimp.2019.105967_b0055","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.3892\/mmr.2017.7739","article-title":"Edaravone protects the retina against ischemia\/reperfusion\u2013induced oxidative injury through the PI3K\/Akt\/Nrf2 pathway","volume":"16","author":"Xu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2019.105967_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01616412.2017.1376457","article-title":"Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK\/Nrf2\/HO-1 signaling pathway","volume":"40","author":"Zhang","year":"2018","journal-title":"Neurol. Res."},{"key":"10.1016\/j.intimp.2019.105967_b0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lfs.2019.02.025","article-title":"Edaravone reduces A\u03b2-induced oxidative damage in SH-SY5Y cells by activating the Nrf2\/ARE signaling pathway","volume":"221","author":"Zhang","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2019.105967_b0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2016.08.048","article-title":"A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model","volume":"633","author":"Fujiwara","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2019.105967_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuint.2017.07.001","article-title":"Neuroprotection of edaravone on the hippocampus of kainate-induced epilepsy rats through Nrf2\/HO-1 pathway","volume":"112","author":"Liu","year":"2018","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.intimp.2019.105967_b0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015441","article-title":"Retrospective study of clinical features and prognosis of edaravone in the treatment of paraquat poisoning","volume":"98","author":"Yi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2019.105967_b0085","first-page":"1131","article-title":"MCI-186 inhibits tumor growth through suppression of EGFR phosphorylation and cell cycle arrest","volume":"25","author":"Suzuki","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2019.105967_b0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/jpet.107.131391","article-title":"The radical scavenger edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) reacts with a pterin derivative and produces a cytotoxic substance that induces intracellular reactive oxygen species generation and cell death","volume":"324","author":"Arai","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0095","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/nass\/nrn287","article-title":"Reactive oxygen species generation through NADH oxidation by pterin derivatives","author":"Nonogawa","year":"2008","journal-title":"Nucleic Acids Symp. Ser. (Oxf.)"},{"key":"10.1016\/j.intimp.2019.105967_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2019.105967_b0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2005.06.039","article-title":"The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB","volume":"229","author":"Kokura","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2019.105967_b0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.compbiolchem.2018.11.022","article-title":"Single crystal XRD, DFT investigations and molecular docking study of 2- ((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)naphthalene-1,4-dione as a potential anti-cancer lead molecule","volume":"78","author":"Rani","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.intimp.2019.105967_b0115","doi-asserted-by":"crossref","first-page":"980","DOI":"10.5732\/cjc.010.10309","article-title":"A cell-based screen for anticancer activity of 13 pyrazolone derivatives","volume":"29","author":"Wang","year":"2010","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.intimp.2019.105967_b0120","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bbrc.2004.06.094","article-title":"A novel pyrazolone, 4,4-dichloro-1-(2,4-dichlorophenyl)-3-methyl-5-pyrazolone, as a potent catalytic inhibitor of human telomerase","volume":"320","author":"Kakiuchi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2019.105967_b0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bioorg.2010.10.003","article-title":"Synthesis, antitumor activity and QSAR studies of some 4-aminomethylidene derivatives of edaravone","volume":"39","author":"Markovi\u0107","year":"2011","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.intimp.2019.105967_b0130","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.bmcl.2016.03.024","article-title":"Synthesis, molecular properties prediction and anticancer, antioxidant evaluation of new edaravone derivatives","volume":"26","author":"Polkam","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2019.105967_b0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2016.08.003","article-title":"Edaravone alleviates cisplatin-induced neurobehavioral deficits via modulation of oxidative stress and inflammatory mediators in the rat hippocampus","volume":"791","author":"Jangra","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2019.105967_b0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.heares.2015.08.004","article-title":"Protective role of edaravone against cisplatin-induced ototoxicity in an auditory cell line","volume":"330","author":"Im","year":"2015","journal-title":"Hear. Res."},{"key":"10.1016\/j.intimp.2019.105967_b0145","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijporl.2013.04.003","article-title":"Protective effects of edaravone against cisplatin-induced hair cell damage in zebrafish","volume":"77","author":"Hong","year":"2013","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/j.intimp.2019.105967_b0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(02)02251-3","article-title":"Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats","volume":"451","author":"Sueishi","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2019.105967_b0155","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1124\/jpet.102.047522","article-title":"A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo","volume":"305","author":"Satoh","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/10715760310001646886","article-title":"Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney","volume":"38","author":"Iguchi","year":"2004","journal-title":"Free Radic Res."},{"key":"10.1016\/j.intimp.2019.105967_b0165","article-title":"Effect of edaravone against cisplatin-induced chronic renal injury","volume":"1\u201310","author":"Koike","year":"2019","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.intimp.2019.105967_b0170","doi-asserted-by":"crossref","DOI":"10.2174\/1574886314666190506100717","article-title":"Protective effect of edaravone on cyclophoshamide induced oxidative stress and neurotoxicity in rats","author":"Singh","year":"2019","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.intimp.2019.105967_b0175","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1253\/circj.71.1815","article-title":"Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death","volume":"71","author":"Ikegami","year":"2007","journal-title":"Circ. J."},{"key":"10.1016\/j.intimp.2019.105967_b0180","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1248\/bpb.34.1523","article-title":"Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs","volume":"34","author":"Xin","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.intimp.2019.105967_b0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neulet.2010.08.065","article-title":"A free-radical scavenger protects the neural progenitor cells in the dentate subgranular zone of the hippocampus from cell death after X-irradiation","volume":"485","author":"Motomura","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2019.105967_b0190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1269\/jrr.07061","article-title":"Free radical scavenger edaravone suppresses x-ray-induced apoptosis through p53 inhibition in MOLT-4 cells","volume":"48","author":"Sasano","year":"2007","journal-title":"J Radiat Res."},{"key":"10.1016\/j.intimp.2019.105967_b0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/09553002.2012.715791","article-title":"Lineal energy-based evaluation of oxidative DNA damage induced by proton beams and X-rays","volume":"89","author":"Hong","year":"2013","journal-title":"Int. J. Radiat Biol."},{"key":"10.1016\/j.intimp.2019.105967_b0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12192-014-0542-3","article-title":"Edaravone protects human peripheral blood lymphocytes from \u03b3-irradiation-induced apoptosis and DNA damage","volume":"20","author":"Chen","year":"2015","journal-title":"Cell Stress Chaperones."},{"key":"10.1016\/j.intimp.2019.105967_b0205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2009.12.020","article-title":"Edaravone, a known free radical scavenger, enhances X-ray-induced apoptosis at low concentrations","volume":"293","author":"Sasano","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2019.105967_b0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1269\/jrr.45.319","article-title":"In vivo radioprotection of mice by 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone; Radicut), a clinical drug","volume":"45","author":"Anzai","year":"2004","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.intimp.2019.105967_b0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neulet.2007.07.029","article-title":"The free-radical scavenger edaravone restores the differentiation of human neural precursor cells after radiation-induced oxidative stress","volume":"423","author":"Ishii","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2019.105967_b0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11060-014-1573-4","article-title":"Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial","volume":"120","author":"Tang","year":"2014","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.intimp.2019.105967_b0225","first-page":"CD011492","article-title":"Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery","volume":"7","author":"Chung","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2019.105967_b0230","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jphs.2015.02.001","article-title":"Evaluation of edaravone against radiation-induced oral mucositis in mice","volume":"127","author":"Nakajima","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2019.105967_b0235","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2334\/josnusd.18-0405","article-title":"Suppression of parotid acinar cell dysfunction by the free radical scavenger 3-methyl-1-phenyl-2-pyrazolin-5-one","volume":"61","author":"Sakurai","year":"2019","journal-title":"J. Oral Sci."},{"key":"10.1016\/j.intimp.2019.105967_b0240","first-page":"2037","article-title":"Edaravone ameliorates experimental autoimmune thyroiditis in rats through HO-1-dependent STAT3\/PI3K\/Akt pathway","volume":"10","author":"Li","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.intimp.2019.105967_b0245","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.intimp.2019.105967_b0250","first-page":"1","article-title":"Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment","volume":"2019","author":"Meng\u00edbar","year":"2019","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.intimp.2019.105967_b0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13000-019-0832-2","article-title":"IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis","volume":"14","author":"Han","year":"2019","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.intimp.2019.105967_b0260","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12022-019-9579-2","article-title":"Pembrolizumab-induced thyroiditis","volume":"30","author":"Imblum","year":"2019","journal-title":"Endocr Pathol."},{"key":"10.1016\/j.intimp.2019.105967_b0265","first-page":"55","article-title":"The association between cancer and amyotrophic lateral sclerosis","volume":"2","author":"Freedman","year":"2013","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.intimp.2019.105967_b0270","first-page":"6","article-title":"ALS and cancer","volume":"7","author":"Yamaguchi","year":"2016","journal-title":"J. Carciong. Mutagen"},{"key":"10.1016\/j.intimp.2019.105967_b0275","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2741\/4777","article-title":"Cancer-related genes and ALS","volume":"24","author":"Yamamoto","year":"2019","journal-title":"Front Biosci. (Landmark Ed)."},{"key":"10.1016\/j.intimp.2019.105967_b0280","doi-asserted-by":"crossref","first-page":"E412","DOI":"10.3390\/v10080412","article-title":"Disruption by SaCas9 endonuclease of HERV-Kenv, a retroviral gene with oncogenic and neuropathogenic potential, inhibits molecules involved in cancer and amyotrophic lateral sclerosis","volume":"10","author":"Ibba","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2019.105967_b0285","doi-asserted-by":"crossref","first-page":"96697","DOI":"10.18632\/oncotarget.18043","article-title":"Riluzole: a potential therapeutic intervention in human brain tumor stem-like cells","volume":"8","author":"Sperling","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.intimp.2019.105967_b0290","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/pcmr.12694","article-title":"A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma","volume":"31","author":"Mehnert","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.intimp.2019.105967_b0295","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/pros.23719","article-title":"Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells","volume":"79","author":"Wadosky","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.intimp.2019.105967_b0300","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1871520618666180228152713","article-title":"Riluzole inhibits proliferation, migration and cell cycle progression and induces apoptosis in tumor cells of various origins","volume":"18","author":"Lemieszek","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.intimp.2019.105967_b0305","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.18632\/oncotarget.26854","article-title":"The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, in vitro and in vivo","volume":"10","author":"Khan","year":"2019","journal-title":"Oncotarget."},{"key":"10.1016\/j.intimp.2019.105967_b0310","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-016-3816-x","article-title":"Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1","volume":"157","author":"Speyer","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2019.105967_b0315","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027770","article-title":"Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup","volume":"9","author":"Kerckhove","year":"2019","journal-title":"BMJ Open."},{"key":"10.1016\/j.intimp.2019.105967_b0320","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123249","article-title":"Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS","volume":"3","author":"Trias","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.intimp.2019.105967_b0325","first-page":"1","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial","author":"Mora","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"key":"10.1016\/j.intimp.2019.105967_b0330","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1016\/j.bmc.2013.12.046","article-title":"Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease","volume":"22","author":"Brunden","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.intimp.2019.105967_b0335","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fncel.2018.00226","article-title":"Repositioning microtubule stabilizing drugs for brain disorders","volume":"12","author":"Varidaki","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.intimp.2019.105967_b0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210752","article-title":"Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS","volume":"14","author":"Rando","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2019.105967_b0345","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000223353.34006.54","article-title":"Neuroprotective agents for clinical trials in ALS: a systematic assessment","volume":"67","author":"Traynor","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2019.105967_b0350","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12929-016-0290-z","article-title":"Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS","volume":"23","author":"Chang","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2019.105967_b0355","first-page":"751","article-title":"Antioxidant effects of celastrol against hydrogen peroxide-induced oxidative stress in the cell model of amyotrophic lateral sclerosis","volume":"69","author":"Li","year":"2017","journal-title":"Sheng Li Xue Bao"},{"key":"10.1016\/j.intimp.2019.105967_b0360","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/2051-5960-2-66","article-title":"CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis","volume":"2","author":"Evans","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.intimp.2019.105967_b0365","doi-asserted-by":"crossref","first-page":"S5.004","DOI":"10.1212\/WNL.92.15_supplement.S5.004","article-title":"Cancer drug repurposing for treating amyotrophic lateral sclerosis (ALS) (S5.004)","volume":"92","author":"Lukas","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2019.105967_b0370","doi-asserted-by":"crossref","first-page":"E2826","DOI":"10.3390\/ijms20112826","article-title":"RTA 408 inhibits interleukin-1\u03b2-induced MMP-9 expression via suppressing protein kinase-dependent NF-\u03baB and AP-1 activation in rat brain astrocytes","volume":"20","author":"Yang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2019.105967_b0375","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s10753-019-01046-6","article-title":"Nrf2 Activator RTA-408 protects against ozone-induced acute asthma exacerbation by suppressing ROS and \u03b3\u03b4T17 cells","volume":"42","author":"Zhang","year":"2019","journal-title":"Inflammation."},{"key":"10.1016\/j.intimp.2019.105967_b0380","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.2147\/OTT.S136992","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors","volume":"10","author":"Creelan","year":"2017","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.intimp.2019.105967_b0390","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3892\/etm.2011.281","article-title":"Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction","volume":"2","author":"Kikuchi","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.intimp.2019.105967_b0395","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00280-007-0459-y","article-title":"Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria","volume":"61","author":"Santos","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2019.105967_b0400","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1515\/jbcpp-2018-0191","article-title":"Protective mechanisms of protocatechuic acid against doxorubicin-induced nephrotoxicity in rat model","volume":"30","author":"Molehin","year":"2019","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.intimp.2019.105967_b0405","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2147\/DDDT.S172612","article-title":"Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review","volume":"12","author":"Sova","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.11.017","article-title":"NRF2 and NF-\u049bB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches","volume":"21","author":"Sivandzade","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2019.105967_b0415","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.phrs.2017.12.034","article-title":"Targeting oncogenic transcription factors by polyphenols: a novel approach for cancer therapy","volume":"130","author":"Rajagopal","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2019.105967_b0420","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.phrs.2019.04.004","article-title":"Honokiol for cancer therapeutics: a traditional medicine that can modulate multiple oncogenic targets","volume":"144","author":"Banik","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2019.105967_b0425","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1021\/acschemneuro.8b00290","article-title":"Honokiol alleviates oxidative stress-induced neurotoxicity via activation of Nrf2","volume":"9","author":"Hou","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.intimp.2019.105967_b0430","article-title":"Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity","volume":"102285","author":"\u00c1lvarez-Sierra","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2019.105967_b0435","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1507\/endocrj.EJ18-0396","article-title":"Upregulated tissue expression of T helper (Th) 17 pathogenic interleukin (IL)-23 and IL-1\u03b2 in Hashimoto's thyroiditis but not in Graves' disease","volume":"66","author":"Zake","year":"2019","journal-title":"Endocr. J."},{"key":"10.1016\/j.intimp.2019.105967_b0440","doi-asserted-by":"crossref","first-page":"115028","DOI":"10.18632\/oncotarget.22854","article-title":"Dihydroartemisinin attenuates autoimmune thyroiditis by inhibiting the CXCR3\/PI3K\/AKT\/NF-\u03baB signaling pathway","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.intimp.2019.105967_b0445","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejps.2018.07.052","article-title":"Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats","volume":"123","author":"Hyung","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2019.105967_b0450","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S161944","article-title":"Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model","volume":"12","author":"Parikh","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0455","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2147\/DDDT.S161940","article-title":"Self-nanomicellizing solid dispersion of edaravone: part I - oral bioavailability improvement","volume":"12","author":"Parikh","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0460","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.clinthera.2018.08.009","article-title":"Bioavailability of edaravone sublingual tablet versus intravenous infusion in healthy male volunteers","volume":"40","author":"Wang","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2019.105967_b0465","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejps.2018.04.002","article-title":"Gastric retention pellets of edaravone with enhanced oral bioavailability: absorption mechanism, development, and in vitro\/in vivo evaluation","volume":"119","author":"Li","year":"2018","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919320454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919320454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:17:08Z","timestamp":1761585428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919320454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":93,"alternative-id":["S1567576919320454"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105967","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105967"}}